MACC1 enhances an oncogenic RNA splicing of IRAK1 through interacting with HNRNPH1 in lung adenocarcinoma
Journal of Cellular Physiology · 2024
DOI: 10.1002/jcp.31426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Physiology, 2024. Verfasst von Shiqing Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery & Lung Cancer Diagnosis and Treatment Center of Dalian, The First Affiliated Hospital of Dalian Medical University, Da…. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Associated Kinases, Trans-Activators, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Science and Technology Innovation Talent Support Program of Dalian, National Natural Science Foundation of China.
Abstract (Originalsprache)
Dysregulation of alternative pre‐mRNA splicing plays a critical role in the progression of cancers, yet the underlying molecular mechanisms remain largely unknown. It is reported that metastasis‐associated in colon cancer 1 (MACC1) is a novel prognostic and predictive marker in many types of cancers, including lung adenocarcinoma. Here, we reveal that the oncogene MACC1 specifically drives the progression of lung adenocarcinoma through its control over cancer‐related splicing events. MACC1 depletion inhibits lung adenocarcinoma progression through triggering IRAK1 from its long isoform, IRAK1‐L, to the shorter isoform, IRAK1‐S. Mechanistically, MACC1 interacts with splicing factor HNRNPH1 to prevent the production of the short isoform of IRAK1 mRNA. Specifically, the interaction between MACC1 and HNRNPH1 relies on the involvement of MACC1's SH3 domain and HNRNPH1's GYR domain. Further, HNRNPH1 can interact with the pre‐mRNA segment (comprising exon 11) of IRAK1, thereby bridging MACC1's regulation of IRAK1 splicing. Our research not only sheds light on the abnormal splicing regulation in cancer but also uncovers a hitherto unknown function of MACC1 in tumor progression, thereby presenting a novel potential therapeutic target for clinical treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery & Lung Cancer Diagnosis and Treatment Center of Dalian, The First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
- Sino-US Research Center for Cancer Translational Medicine of the Second Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
- Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
ORCID-Profile: Chundong Gu
Förderung
- Science and Technology Innovation Talent Support Program of Dalian
- National Natural Science Foundation of China
Zitieren
APA
Wang, S., Li, Z., Chen, C., Guo, T., Zhao, S., Zhao, J., Zhang, W., Qi, Y., Zhang, J., Wang, Y., Lv, Y., & Gu, C. (2024). MACC1 enhances an oncogenic RNA splicing of IRAK1 through interacting with HNRNPH1 in lung adenocarcinoma. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.31426
Vancouver
Wang S, Li Z, Chen C, Guo T, Zhao S, Zhao J, et al. MACC1 enhances an oncogenic RNA splicing of IRAK1 through interacting with HNRNPH1 in lung adenocarcinoma. Journal of Cellular Physiology. 2024. doi:10.1002/jcp.31426
BibTeX
@article{Wang2024,
author = {Wang, Shiqing and Li, Zhuoshi and Chen, Chaoqun and Guo, Tao and Zhao, Shilei and Zhao, Jinyao and Zhang, Wenjing and Qi, Yangfan and Zhang, Jinrui and Wang, Yang and Lv, Yuesheng and Gu, Chundong},
title = {MACC1 enhances an oncogenic RNA splicing of IRAK1 through interacting with HNRNPH1 in lung adenocarcinoma},
journal = {Journal of Cellular Physiology},
year = {2024},
doi = {10.1002/jcp.31426}
}
EUVIMED